A Phase 1, Three-Part, Open-Label, Parallel-Cohort Safety and Tolerability Study of Relugolix in Combination with Abiraterone Acetate Plus a Corticosteroid, Apalutamide, or Docetaxel with or Without Prednisone in Men with Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer
Latest Information Update: 27 Sep 2024
At a glance
- Drugs Abiraterone acetate (Primary) ; Relugolix (Primary) ; Apalutamide; Docetaxel; Methylprednisolone; Prednisone
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions
- Sponsors Myovant Sciences; Sumitomo Pharma America
- 20 Sep 2024 Planned End Date changed from 29 May 2024 to 29 May 2025.
- 20 Sep 2024 Planned primary completion date changed from 29 May 2024 to 29 May 2025.
- 17 May 2024 Planned End Date changed from 1 Nov 2023 to 29 May 2024.